Two manufacturers of the abortion pill mifepristone filed emergency appeals with the Supreme Court over the weekend, asking the justices to block a Fifth Circuit ruling that reinstated a requirement for the drug to be prescribed and dispensed in person, reversing a Biden-era policy that allowed mail-order distribution nationwide.

Delaware-based Danco Laboratories and GenBioPro both filed their requests on Saturday, one day after a three-judge panel of the Fifth U.S. Circuit Court of Appeals sided with Louisiana and issued a temporary nationwide injunction. The order restores a 2021 rule requiring patients to obtain mifepristone through an in-person visit, effectively shutting down the telehealth prescribing and mail dispensing pipeline that had operated since the FDA dropped that requirement under former President Biden.

The case lands on the Supreme Court's doorstep at a moment when the justices are already managing a heavy docket of consequential rulings. And it raises a question that should concern every American who cares about federalism and the rule of law: whether a federal agency can unilaterally rewrite drug-dispensing rules in a way that overrides the policy choices of sovereign states.

What the Fifth Circuit actually did

On Friday, the three-judge panel ruled in Louisiana's favor in its case against the Food and Drug Administration. Louisiana officials argued that the Biden administration's loosened rules made it easier for abortion pills to be mailed directly into states where the procedure is mostly banned, an end-run around laws passed by elected state legislatures after the Supreme Court's 2022 Dobbs v. Jackson Women's Health Organization decision returned abortion policy to the states.

The panel found Louisiana was likely to succeed in proving irreparable harm and issued the temporary nationwide injunction. That injunction reinstates the pre-Biden status quo: mifepristone must be prescribed and dispensed in person, just as the FDA required through 2021.

Louisiana has not been shy about enforcing its own laws. The state has attempted to prosecute out-of-state doctors for providing abortion drugs via mail to Louisiana residents, a fact that underscores just how directly the Biden-era FDA rule clashed with state enforcement.

The manufacturers' arguments

Danco Laboratories filed an emergency motion seeking what its lawyers called an "immediate administrative stay" of the Fifth Circuit's order while the Supreme Court considers the appeal. As The Hill reported, Danco's lawyers framed the ruling in dramatic terms.

"The panel's ruling injects immediate confusion and upheaval into highly time-sensitive medical decisions, and it forces Danco, FDA, certified Mifeprex providers, patients, and pharmacies all to guess at what is allowed and what is not."

In a separate filing dated May 2, Danco's lawyers described the situation as "regulatory whiplash" and said the Fifth Circuit's order "forces patients, providers, and pharmacies into immediate uncertainty, with no transition period and no practical guidance."

GenBioPro, the second mifepristone manufacturer, filed its own emergency appeal the same day. CEO Evan Masingill told The Hill that the company views the Fifth Circuit's order as an attack on FDA authority itself.

"GenBioPro firmly believes all people have a right to access safe, affordable, evidence-based health care, and we remain concerned that anti-abortion special interests are attempting to undermine the US Food and Drug Administration's regulatory authority."

That framing, casting the dispute as an assault on the FDA rather than a legitimate federalism question, is telling. It sidesteps the core issue: whether the FDA had the authority to remove safety guardrails that had been in place for over two decades, and whether doing so effectively nullified state laws passed after Dobbs.

A pattern of emergency appeals

This is not the first time mifepristone manufacturers have raced to the Supreme Court seeking emergency relief. In a prior round of litigation, Justice Samuel Alito temporarily extended a pause on lower-court restrictions targeting the drug, giving the justices additional time to consider emergency requests from the Biden administration and Danco. Those earlier challenged restrictions would have rolled back FDA actions dating to 2016, including reducing the approved use window from ten weeks to seven weeks of pregnancy and requiring three in-person doctor visits.

The Supreme Court addressed the broader mifepristone question in 2024, when it unanimously rejected a challenge brought by anti-abortion doctors, but on narrow procedural grounds, finding the plaintiffs lacked legal standing. The justices did not rule on the merits of the FDA's regulatory changes. That distinction matters now, because Louisiana's case presents a different plaintiff with a different standing argument: a state whose own laws are being circumvented by a federal agency's dispensing rules.

The Court has shown a willingness this term to weigh in on cases with major institutional stakes, and this dispute sits squarely at the intersection of federal regulatory power and state sovereignty.

The real question no one wants to answer

Mifepristone was approved by the FDA in 2000. For more than twenty years, the in-person dispensing requirement was standard practice. The FDA removed it permanently under the Biden administration, roughly eighteen months before the Supreme Court's 2024 decision. That timeline is worth pausing on.

The removal happened after Dobbs returned abortion policy to the states in 2022. States like Louisiana moved to restrict or ban the procedure through their own legislatures. The Biden FDA's decision to allow mail-order mifepristone created a direct collision: pills could be shipped into states that had democratically chosen to restrict abortion access. Whether you call that "expanding healthcare access" or "federal preemption of state law" depends on your priors. But the tension is real, and the Fifth Circuit's ruling addressed it head-on.

Louisiana's argument is straightforward. If a state bans or heavily restricts abortion, a federal mail-order pipeline that delivers abortion drugs to doorsteps in that state undermines the state's sovereign policy choice. The Biden-era FDA rule didn't just change how a drug was dispensed, it changed where it could reach, and that "where" included states that had explicitly said no.

The manufacturers and their allies frame this as a matter of FDA authority and patient access. Sen. Patty Murray (D-Wash.) posted on social media that "the Fifth Circuit just told millions of women that three judges know better than the FDA, their doctors, and 25 years of evidence." She added: "I have no intention of letting this stand."

But Murray's framing ignores the obvious. The Fifth Circuit didn't question whether mifepristone works. It questioned whether the FDA could strip away an in-person safety requirement in a way that effectively overrode state abortion laws, and whether Louisiana had standing to challenge that decision. The panel said yes.

What happens next

The Supreme Court now faces a familiar choice: intervene quickly with an emergency stay, or let the Fifth Circuit's injunction stand while the case proceeds. In previous rounds of this fight, both the Biden administration and Danco sought emergency relief from the justices to preserve access to the drug while litigation continued. The Court has shown it takes these requests seriously, but the 2024 ruling disposed of the earlier challenge on standing, not substance.

This time, Louisiana presents a stronger standing argument. A state challenging a federal regulation that directly undermines its own enacted laws is a different posture than a group of doctors claiming indirect harm. Whether the justices see it that way remains to be seen.

Several open questions loom. The names of the three Fifth Circuit judges on the panel have not been widely reported. The exact scope and effective timing of the temporary nationwide injunction, beyond the broad requirement to return to in-person dispensing, remain unclear. And it is not yet known how quickly the Supreme Court will act on the emergency motions.

The Court as an institution faces its own pressures heading into another consequential decision, and the mifepristone case adds yet another high-profile emergency to a docket already packed with disputes over federal power.

Meanwhile, the manufacturers describe chaos. Danco's lawyers say providers and pharmacies are left guessing about what is permitted. GenBioPro's CEO calls the ruling "unfounded and baseless." But the in-person dispensing requirement they object to is not some novel invention, it was the FDA's own rule for over two decades. What changed was not the science. What changed was the politics.

The Supreme Court's willingness to take up major constitutional questions this term suggests the justices understand the stakes. The mifepristone fight is not just about one drug. It is about whether a federal agency can use regulatory discretion to override the democratic choices of state governments, and whether the courts will let it.

If the FDA can mail abortion pills into states that ban abortion, the question isn't really about medicine. It's about who gets to make the rules, and whether the rules mean anything at all.